Compare Dover Corp (DOV) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs TransMedics Group Inc — how do they compare? Dover Corp trades at $188.83 (market cap $25.45B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Dover Corp is far larger — about 9.3× TransMedics Group Inc's market cap, and Dover Corp pays a 1.11% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dover Corp for 73 Days and TransMedics Group Inc for 24 Days on average.
| DOV | TMDX | |
|---|---|---|
Market Cap | $25.45B | $2.74B |
Volume | 661,758 | 949,331 |
Sector | Industrials | Health |
52-Week High | $233.31 | $150.42 |
52-Week Low | $161.16 | $61.99 |
Typical Hold Time | 73 Days | 24 Days |
Enterprise Value | $26.95B | $3.13B |
Dividend Yield | 1.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dover Corporation (DOV) trades at $188.96, showing modest daily gains of 0.36%. The stock maintains strong fundamentals with consistent earnings beats and a 67.86% analyst buy rating. Recent acquisitions and product launches demonstrate growth initiatives, while technical indicators signal near-term bearish pressure with support at $186. The company's 13.48% net margin and 14.98% ROE reflect operational efficiency.
DOV presents a compelling investment case with 28% upside to the $243.20 consensus target. Strong cash flow generation and dividend consistency support shareholder returns, though technical weakness and competitive industrial markets pose near-term risks. The upcoming Q3 2026 earnings report on September 30 will be crucial for confirming growth trajectory.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
